Log In
Print this Print this

N9-GP, Pegylated recombinant human Factor IX (PEG-rFIX)

Also known as: formerly NN7999

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionGlyco-pegylated derivative of recombinant human Factor IX
Molecular Target Factor IX
Mechanism of ActionFactor IX replacement
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding episodes in patients with hemophilia B; Treat hemophilia B
Regulatory Designation

Switzerland - Orphan Drug (Treat hemophilia B)


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today